Barreras y estrategias para optimizar el uso de AR GLP-1 en pacientes con diabetes tipo 2 y alto riesgo cardiovascular o enfermedad cardiovascular establecida: Consenso Delphi

Consensus on barriers and strategies for optimal clinical practice use of GLP-1 RAs in patients with type 2 diabetes and high cardiovascular risk or established cardiovascular disease.

Authors: Manuel Gargallo Fernández, Manuel Botana López, Miguel Camafort Babkowski, Raquel Campuzano Ruiz, Ana Cebrián Cuenca, Esther Artime Freire, Silvia Díaz-Cerezo, Miriam Rubio de Santos, Raúl Sanchon, Héctor D. de Paz

Year: 2022

Congress: 63 Congreso Nacional de la Sociedad Española de Endocrinología y Nutrición (SEEN). Las Palmas de Gran Canaria. 26- 28 de octubre del 2022

Download PDF

Subscribe to Outcomes´10

Name

E-mail

Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy

I have read and accepted the privacy policy